2014 Featured Speakers
Hollie Raynor, PhD, RD, LDN
Department of Nutrition
Director, Public Health Nutrition
University of Tennessee
Symposium Topic: Evidence-based practice: The need for efficacy and effectiveness
Hollie Raynor, PhD, RD, LDN, is an Associate Professor and the Director of Public Health Nutrition in the Department of Nutrition at the University of Tennessee. She holds a MS in Public Health Nutrition and a PhD in Clinical Psychology. She conducts research in lifestyle interventions for pediatric and adult weight management, has published over 80 peer-reviewed articles, and has received funding from the National Institutes of Health, American Diabetes Association, and Weight Watcher’s, Int, for her research. She has been selected to be a member of the National Committee for Clinical Guidelines for Obesity by the American Psychological Association, is a faculty member of the Academy of Nutrition and Dietetics’ (AND’s) Adult Weight Management certification program, serves as a member of AND’s Prediabetes Evidence Analysis Library Committee, and was AND’s representative to the 2014 AACE/ACE Obesity Consensus Conference.
Jonathan Wall, PhD
Professor of Medicine
Human Immunology and Cancer Program
Director, Amyloid and Preclinical Molecular Imaging Laboratory
University of Tennessee Graduate School of Medicine
Symposium Topic: TBD
Jonathan Wall is a tenured Professor at the University of Tennessee Graduate School of Medicine, Knoxville, TN. He graduated from the University of Essex (Colchester, UK) with a baccalaureate in biological sciences and moved to the department of Biological Chemistry and Biophysics to pursue a PhD in membrane biophysics, during which time he studied the interactions of proteins with model membrane systems under the tutelage of Prof. Paul O’Shea. After graduating, he moved to the Human Immunology & Cancer Program at the University of Tennessee Medical Center. As a post-doctoral fellow there, he worked on elucidating biochemical and biophysical aspects of immunoglobulin light chain amyloidosis. His work led to the “first-in-human” clinical trial studying the biodistribution, by using PET/CT imaging, of a novel radio-iodinated amyloid fibril-reactive monoclonal antibody in patients with light chain amyloidosis. In addition, he now leads an NIH-funded multidisciplinary team of researchers focused on developing novel therapeutic and molecular imaging agents for amyloid disease, type 2 diabetes, and cancer. In 2005, Dr. Wall was appointed Director of the Preclinical and Diagnostic Molecular Imaging Program, which specializes in using high-resolution, multi-modality micro-imaging technology for visualizing metabolic, pathologic, and anatomic features in small animal models of disease.